05. NEVA DROP ZONE TECHNIQUE
To be used for training purposes once NeVa is already on the shelf and available for use at a customer site. Contact Market Development for help in organizing a NeVa Induction Webinar with your customer if needed.
04. NEW NEVA NET CUSTOMER PRESENTATION
To be used for initial NeVa presentation to target customers.
Contact Market Development for help in organizing a NeVa or NeVa NET Induction Webinar with your customer if needed.
03. NEW NEVA CUSTOMER PRESENTATION
NEW Version including the NeVa CLEAR study results. To be used for initial NeVa presentation to target customers.
Contact Market Development for help in organizing a NeVa Induction Webinar with your customer if needed.
02. NEVA PRODUCT BROCHURE
Product brochure to be used as leave behind piece as needed. This document includes only NeVa codes.
Vesalio Neva Branding Resources
Brand guidelines to show the Vesalio brand is to be used and presented to the public.
Vesalio Secures Class A Funding
Vesalio announces it has successfully secured a Class A financing round. The proceeds will be utilized to support the ongoing US IDE stroke study, establish US infrastructure, expand its innovative product portfolio, and scale international business.
Vesalio Initiates FDA IDE Stroke Study
Vesalio announces another key milestone to support entry into the US neurovascular thrombectomy market. Enrollment has commenced in the Vesalio CLEAR acute ischemic stroke FDA IDE clinical trial utilizing the NeVaTM thrombectomy technology platform.
Vesalio Attains Key FDA Clinical Study Milestone
Vesalio announces it has accomplished a key FDA IDE study milestone to support entry into the US neurovascular market. Enrollment in the VITAL 1 clinical trial, assessing the company’s NeVa VS™ technology in the treatment of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), has been completed.
Vesalio Receives Peripheral FDA 510k Clearance and Additional CE Approval
Vesalio reports it has obtained an FDA 510k clearance and its 4th CE approval. The FDA 510k indication is for the removal of thrombi in peripheral blood vessels.
Vesalio Reports 2,500 Patient Milestone
Vesalio reports it has surpassed 2,500 clinical cases with the NeVa™ neuro-thrombectomy platform. Physicians have evaluated the Neva Drop Zone™ technology with enthusiasm as it has shown a unique capability of removing the full spectrum of clot types in large vessel occlusion ischemic stroke.
